ZIRGAN
GANCICLOVIR USP
| NAME | STRENGTH | PACK SIZE | DOSAGE FORM |
|---|---|---|---|
| ZIRGAN 0.15% W/W | 0.15% W/W | 5 GM | EYE GEL |
Zirgan Eye Gel: Each gram eye gel contains Ganciclovir USP 1.5 mg.
Zirgan (Ganciclovir) contains the active ingredient, Ganciclovir, which is a guanosine derivative that, upon phosphorylation, inhibits DNA replication by herpes simplex viruses (HSV). Ganciclovir is transformed by viral and cellular thymidine kinases (TK) to Ganciclovir triphosphate, which works as an antiviral agent by inhibiting the synthesis of viral DNA in 2 ways: competitive inhibition of viral DNA-polymerase and direct incorporation into viral primer strand DNA, resulting in DNA chain termination and prevention of replication.
Zirgan 0.15% is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).
v Not more than 20 ml should be prescribed at a time.
None to date available
Zirgan is indicated for topical ophthalmic use only. Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with Zirgan.
Most common adverse reactions reported in patients are blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
Pregnancy category C; There are no adequate and well-controlled studies in pregnant women. Zirgan should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation: It is not known whether topical ophthalmic Ganciclovir administration could result in sufficient systemic absorption to produce detectable quantities in breast milk. Caution should be exercised when Zirgan is administered to nursing mothers.
No Information Establisted
No information provided.
Store at 15°C-25°C. Do not freeze.
Zirgan Eye Gel: Each tube contains 5 gm sterile eye gel.